Bullboard Post History

by Riverfolk

Order by:

V.ARCH	Arch - Fully Funded Phase III Human Trial Approved LSALT Peptide has completed an international Phase II trial targeting organ... March 4, 2022
V.HCH	HCH NEWS - Glencore Offtake agreement News Release March 2, 2022
V.ARCH	University of Calgary Article Article February 28, 2022
V.HCH	New Chairman - Sprott Insider !! HCH News Release!! February 28, 2022
V.ARCH	Arch Biopartners - Venture Top 50 2022 {^youtubevideo\|(width)425\|(height)264\|(rel)False\|(url)https://www.youtube.com... February 24, 2022
V.HCH	HCH RIU Presentation {^youtubevideo\|(width)425\|(height)264\|(rel)False\|(url)https://www.youtube.com... February 16, 2022
V.ARCH	METABLOK - AKI {^youtubevideo\|(width)425\|(height)264\|(rel)False\|(url)https://www... February 3, 2022
V.ARCH	Metablok - A pathway to an unmet 20 billion market Recently Arch Biopartners released a glimpse of the human data waiting on... February 3, 2022
V.ARCH	Arch Scientists Publish Data on the Mechanism of Action and TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or... February 3, 2022
V.HCH	Accumulating a position here 1) 6-8 weeks till resource estimate 2) feasibility study in Q3 3) alot of... January 21, 2022
V.ARCH	RE:When r we going to get trial results news? The company announced trial results in early December, at that time it was... January 12, 2022
V.ARCH	Todays House Positions House Positions for C:ARCH from 20220104 to 20220104... January 4, 2022
V.ARCH	Todays House Positions House Positions for C:ARCH from 20211231 to 20211231... December 31, 2021
V.ARCH	ARCH - Sepsis-Induced Inflammation & AKI inhibited by LSALT December 30, 2021
V.ARCH	ARCH - Metablok Preserves Kidney Function December 30, 2021
V.ARCH	ARCH - Dipeptidase-1 and the Kidney December 30, 2021
V.ARCH	Arch - Novel Therapeutic Developers Explain Technology Overview of the LSALT Peptide Program December 30, 2021
V.ARCH	ARCH - Intellectual Property Intellectual Property MetaBlok was invented by Arch scientists Dr. Stephen... December 30, 2021
V.ARCH	ARCH - FULLY FUNDED PHASE III Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments... December 30, 2021
V.ARCH	ARCH -Third Party Validation of Mechanism of Action Dipeptidase-1 December 30, 2021

Become a member today, It's free!

Bullboard Post History

by Riverfolk

Arch - Fully Funded Phase III Human Trial Approved

HCH NEWS - Glencore Offtake agreement

University of Calgary Article

New Chairman - Sprott Insider !!

Arch Biopartners - Venture Top 50 2022

HCH RIU Presentation

METABLOK - AKI

Metablok - A pathway to an unmet 20 billion market

Arch Scientists Publish Data on the Mechanism of Action and

Accumulating a position here

RE:When r we going to get trial results news?

Todays House Positions

Todays House Positions

ARCH - Sepsis-Induced Inflammation & AKI inhibited by LSALT

ARCH - Metablok Preserves Kidney Function

ARCH - Dipeptidase-1 and the Kidney

Arch - Novel Therapeutic Developers Explain Technology

ARCH - Intellectual Property

ARCH - FULLY FUNDED PHASE III

ARCH -Third Party Validation of Mechanism of Action

Featured News Links

Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments

Featured Company

AKITA Drilling Ltd T.AKT.A

Become a member today, It's free!

Sign In

Send my password

Become a member today, It's free!

Bullboard Post History

by Riverfolk

Featured News Links

Featured Company